1. Home
  2. MGN vs SNGX Comparison

MGN vs SNGX Comparison

Compare MGN & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MGN

Megan Holdings Limited Ordinary Shares

HOLD

Current Price

$0.10

Market Cap

6.5M

Sector

N/A

ML Signal

HOLD

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$0.37

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MGN
SNGX
Founded
2020
1987
Country
Malaysia
United States
Employees
4
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5M
5.6M
IPO Year
N/A
2006

Fundamental Metrics

Financial Performance
Metric
MGN
SNGX
Price
$0.10
$0.37
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
13.5M
539.9K
Earning Date
05-12-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.03
EPS
N/A
N/A
Revenue
N/A
$119,371.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$32.33
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.10
$0.28
52 Week High
$5.18
$6.23

Technical Indicators

Market Signals
Indicator
MGN
SNGX
Relative Strength Index (RSI) 34.41 40.78
Support Level N/A $0.37
Resistance Level $0.16 $0.41
Average True Range (ATR) 0.02 0.02
MACD -0.00 0.01
Stochastic Oscillator 5.83 37.70

Price Performance

Historical Comparison
MGN
SNGX

About MGN Megan Holdings Limited Ordinary Shares

Megan Holdings Ltd is principally engaged in the development, construction and maintenance of aquaculture farms and related works. Its operations are based in Malaysia. The company's operating segments include: Aquaculture and agriculture; Industrial solutions; and Investment in marketable securities. It derives maximum revenue from Aquaculture and agriculture, which involves development, construction, and maintenance of aquaculture and agriculture farms and related works.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

Share on Social Networks: